HENLIUS (02696) surged over 10% today, rising 9.33% to HK$77.95 with a trading volume of HK$82.34 million as of press time.

On the news front, FOSUN PHARMA's Middle East office and joint venture company Fosunhenlius Middle East United Company officially opened in Jeddah, Saudi Arabia, marking a crucial step in the company's localized operations in the Middle East region. The joint venture was established by HENLIUS, a subsidiary of FOSUN PHARMA, in partnership with leading Saudi pharmaceutical company SVax. The collaboration will integrate global R&D resources with local advantages to provide affordable, high-quality biologics to patients in the Middle East, North Africa, and Turkey regions.

According to public information, in November 2024, HENLIUS reached a strategic cooperation agreement with Saudi Arabia's SVax. The two parties will establish separate commercialization and manufacturing joint ventures in Saudi Arabia, and collaborate on the development of a series of HENLIUS products in the MENAT region, including adalimumab Handayuan (HLX03) and bevacizumab Hanbeitai (HLX04), covering local registration, production, and commercialization.

Additionally, the first batch of projects under this cooperation framework includes joint investment in the development of HENLIUS's self-developed pembrolizumab biosimilar HLX17, jointly promoting the global registration and market launch of this product.